Editas Medicine, Inc. (EDIT)
| Market Cap | 485.31M +102.1% |
| Revenue (ttm) | 47.01M +20.8% |
| Net Income | -73.95M |
| EPS | -0.73 |
| Shares Out | 153.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,271,503 |
| Open | 3.250 |
| Previous Close | 3.300 |
| Day's Range | 3.150 - 3.410 |
| 52-Week Range | 1.660 - 4.537 |
| Beta | 2.06 |
| Analysts | Buy |
| Price Target | 6.00 (+89.87%) |
| Earnings Date | Aug 5, 2026 |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated ... [Read more]
Financial Performance
In 2025, Editas Medicine's revenue was $40.52 million, an increase of 25.39% compared to the previous year's $32.31 million. Losses were -$160.06 million, -32.49% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 89.87% from the latest price.
News
Editas Medicine initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Editas Medicine (EDIT) with a Buy rating and $6 price target
Editas Medicine reports Q2 EPS (15c), consensus (28c)
Reports Q2 revenue $11.89M, consensus $2.75M. The revenue increase was primarily attributable to the recognition of deferred revenue related to the expiration certain rights to opt-in to additional re...
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, incl...
Editas Medicine Earnings release: Q2 2026
Editas Medicine released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Editas Medicine Quarterly report: Q2 2026
Editas Medicine has published its Q2 2026 quarterly earnings report on August 5, 2026.
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.
Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 t...
Editas Medicine Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification, all of which passed. Strategic updates focused on EDIT-401's clinical progress and a major public offering to fund development. No questions were raised by stockholders during the session.
Editas Medicine Transcript: Jefferies Global Healthcare Conference 2026
A novel CRISPR-based therapy, EDIT-401, demonstrated durable 90% reductions in LDL cholesterol and Lp(a) in preclinical studies, targeting high-risk cardiovascular patients. Clinical trials are set to begin in Australia in 2024, with top-line data expected in 2027.
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today an...
Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI
After Editas Medicine (EDIT) presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral presentation at the European Atherosclerosis Society Congress, Evercore ISI...
TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’
TD Cowen notes that Editas Medicine (EDIT) presented “compelling preclinical data” at EAS detailing EDIT-401’s 90% reduction in low-density lipoprotein cholesterol, apolipoprotein B and lipoprotein(a)...
Editas Medicine 55.6M share Secondary priced at $2.25
Cantor Fitzgerald and Wells Fargo acted as joint book running managers for the offering.
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the...
Editas Medicine announces common stock, warrant offering, no amount given
Editas Medicine (EDIT) announced that it has commenced an underwritten public offering of its common stock and accompanying warrants to purchase shares of common stock. All of the securities in…
Editas Medicine Announces Proposed Public Offering
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced tha...
Editas Medicine presented preclinical data for EDIT-401 at EAS Congress
Editas Medicine (EDIT) presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral presentation at the 94th European Atherosclerosis Society, or EAS, Congress in At...
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent eff...
Editas Medicine’s EDIT-401 shows efficacy and safety in hyperlipidemia
Editas Medicine (EDIT) shared new preclinical data supporting the continued advancement of Editas’ lead in vivo development candidate, EDIT-401, and its potential as a one-time treatment for hyperlipi...
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 months New data demonstrate promising preclin...
Editas Medicine reports Q1 EPS (26c), consensus (24c)
Reports Q1 revenue $2.83M, consensus $5.94M. “In the first quarter, we continued to advance EDIT-401, a potentially transformative in vivo gene editing medicine designed to treat hyperlipidemia, towar...
Editas Medicine Announces First Quarter 2026 Results and Business Updates
EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026 Company to present new EDIT-401 preclinical data ...
Editas Medicine Earnings release: Q1 2026
Editas Medicine released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Editas Medicine Quarterly report: Q1 2026
Editas Medicine has published its Q1 2026 quarterly earnings report on May 5, 2026.
Editas Medicine Proxy statement: Proxy filing
Editas Medicine filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.